Ethical, Legal, and Regulatory Issues Regarding the Study and Use of Medications in Pregnant Women




Despite the prevalence of off-label drug prescriptions for pregnant women, little attention is paid to the ethical, legal, and regulatory issues regarding this practice. This paper discusses some of these key issues relevant to the practice of off-label medication use by women during pregnancy.


Doering, P. (2002). Review of pregnancy labeling of prescription drugs:is the current system adequate to inform of risks?. Am J Obstet Gynecol, 187(2), 333-339. doi: 10.1067/mob.2002.125740

Kim, J., & Scialli, A. (2011). Thalidomide: The tragedy of birth defects and the effective treatment of disease.Toxicological Sciences, 122(1), 1-6. doi: 10.1093/toxsci/kfr088 - The Most Trusted Source for FDA-Approved Full .... (2014, January 1). The Physicians' Desk Reference. Retrieved , from

Duke Medicine News and Communications. (2010, July 15). An ethical argument: Include pregnant women in research. Duke Medicine, pp. 1-2.

Centers for disease control and prevention, (2013). Data & statistics: Uses of medications in pregnant women

Peters , S et al. (2013). Safe lists for medications in pregnancy: Inadequate evidence base and inconsistent guidance from web-based information, 2011.Pharmacoepidemiology and Drug Safety, 22, 324-328. doi: 10.1002/pds.3410

Lyerly, A et al (2001). The second wave: Toward responsible inclusion of pregnant women in research.International Journal of Feminist Approaches to Bioethics, 1(2), 5-22.

Piper, J et al. (1992). Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstetrics & Gynecology, 80(3), 429-432.

Ornoy, A. (2009). Valproic Acid In Pregnancy: How Much Are We Endangering The Embryo And Fetus?. Reproductive Toxicology, 28, 1-10.

Yang Q et al (1997). The return of thalidomide: Are birth defect surveillance systems ready? American Journal of Medical Genetics, 73, 251-258.

Boothby LA & Doering PL (2001). FDA labeling system for drugs in pregnancy. The Annals of Pharmacotherapy. 35, 1485-1489.

Food and Drug Administration, Consumer Health Information. (2008). Pregnant women to benefit from better information. Retrieved from website:

Food and Drug Administration, Consumer Health Information. (2011). Pregnancy and lactation labeling. Retrieved from website:

Charo, R. (1993). Protecting us to death: Women, pregnancy, and clinical research trials. Saint Louis University Law Journal, 38(135), 135187.

Merkatz, R. (1993). Women in clinical trials of new drugs: A change in food and drug administration policy. The New England Journal of Medicine, 329(4), 292-296.

Feibus, K et al (2011). Pregnant women & clinical trials: Scientific, regulatory, and ethical considerations. Presentation. PMHS. FDA Office of Women’s Symposium. 17 May 2011.

Kessler, D. (1993). Introducing medwatch. JAMA, 269(21), 2765-1768.

Beard K (1992). Adverse reactions as a cause of hospital admission in the aged. Drugs Aging. 1992:2

Faden, R. (2010). Justice in health research: Beyond protection from risks. Enrolling Pregnant Women in Research, 20-23.

Jackson, J. (1992). Pharmaceutical product liability may be hazardous to your health: A no-fault alternative to concurrent regulation. The American University Law Review, 42, 199-237. P. 204

Brody, J. (1983, June 19). Shadow of doubt wipes out bendectin. The new york times. Retrieved from

Sindell v. Abbott Laboratories et al (1980). 26 Cal 3d 588

Walsh CJ and Klein MS (1986). The conflicting objectives of federal and state tort law drug regulation. Food Drug Cosmetic Law Journal 41, 171-194

Henry, V. (1999). Off-label prescribing: Legal implications.The Journal of Legal Medicine, 20, 365-383.

Get Whooping Cough Vaccine While You Are Pregnant. (2014, January 17). Centers for Disease Control and Prevention. Retrieved , from

Whooping Cough Vaccines are Safe but Side Effects Can Occur. (2014, January 17). Centers for Disease Control and Prevention. Retrieved , from

Lori B et al (2004). Risks of untreated depression during pregnancy. Canadian Family Physician, 50, 37-39

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.